# Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

> **NCT02366884** · PHASE2 · UNKNOWN · sponsor: **Dr. Frank Arguello Cancer Clinic** · enrollment: 250 (estimated)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Anti-Bacterial Agents
- **DRUG:** Anti-Fungal Agents
- **DRUG:** Anti-Protozoal Agents

## Key facts

- **NCT ID:** NCT02366884
- **Lead sponsor:** Dr. Frank Arguello Cancer Clinic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-07-26
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366884, "Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02366884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*